Contemporary Pharmacologic Treatments for Spasticity of the Upper Limb After Stroke: A Systematic Review

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Muscle spasticity after stroke may be painful and severe and may restrict the patient's ability to perform routine daily tasks, particularly when the affected muscles are in the upper limbs. Treatments targeted at reducing this spasticity have evolved over time. Objective: This was a systematic review of recent studies focusing on contemporary pharmacologic therapies for upper limb spasticity after stroke. Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched for clinical trials published in English from January 1995 to July 2010 using search terms that included spasticity, stroke, hemiplegia, phenol, baclofen, tizanidine, dantrolene, benzodiazepine, and botulinum toxin. The level of evidence of the identified publications was assessed using the Oxford Centre for Evidence-Based Medicine criteria. Results: A total of 113 potentially relevant articles were identified by the search; of these, 54 studies were included in the review (23 randomized controlled trials [RCTs] and 31 open-label, nonrandomized, or observational studies). Of these, 51 involved treatment with botulinum toxin (BTX). All studies assessed spasticity; some also assessed additional outcomes, such as pain, disability, and functional status. Thirty-eight clinical trials reported a significant reduction in spasticity with BTX, either compared with baseline or with placebo (P < 0.05). A head-to-head comparison found a significant reduction in spasticity with BTX injections compared with oral tizanidine (TZD) (P < 0.001). Two studies of intrathecal baclofen (ITB) reported significant reductions in upper limb spasticity after 12 months of treatment, and 1 study of tizanidine reported significant reductions in upper limb spasticity after 16 weeks of treatment (all, P < 0.001). General or local weakness, injection-site pain, and fatigue were the most frequently reported adverse events with BTX type A, and dry mouth was the most frequently reported adverse event with BTX type B. No serious or life-threatening adverse events were reported in any trial of BTX. Conclusions: The 54 studies included in this systematic review of treatments for upper limb spasticity after stroke measured multiple outcomes using a variety of instruments. Fifty-one studies focused on treatment with a BTX formulation. BTX appeared to be an effective and well-tolerated focal treatment for reducing tonicity in patients with upper limb spasticity after stroke, supporting current guideline recommendations.

Original languageEnglish (US)
Pages (from-to)2282-2303
Number of pages22
JournalClinical Therapeutics
Volume32
Issue number14
DOIs
StatePublished - Dec 2010

Fingerprint

Botulinum Toxins
Upper Extremity
Stroke
Baclofen
Therapeutics
Clinical Trials
Dantrolene
Pain
Type A Botulinum Toxins
Injections
Aptitude
Hemiplegia
Muscle Spasticity
Evidence-Based Medicine
Phenol
Benzodiazepines
MEDLINE
Observational Studies
Fatigue
Mouth

Keywords

  • Botulinum toxin
  • Spasticity
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Contemporary Pharmacologic Treatments for Spasticity of the Upper Limb After Stroke : A Systematic Review. / Olvey, Eleanor L.; Armstrong, Edward P; Jones-Grizzle, Amy J.

In: Clinical Therapeutics, Vol. 32, No. 14, 12.2010, p. 2282-2303.

Research output: Contribution to journalArticle

@article{48d23f87349446a5ba3eb3f9ba277c02,
title = "Contemporary Pharmacologic Treatments for Spasticity of the Upper Limb After Stroke: A Systematic Review",
abstract = "Background: Muscle spasticity after stroke may be painful and severe and may restrict the patient's ability to perform routine daily tasks, particularly when the affected muscles are in the upper limbs. Treatments targeted at reducing this spasticity have evolved over time. Objective: This was a systematic review of recent studies focusing on contemporary pharmacologic therapies for upper limb spasticity after stroke. Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched for clinical trials published in English from January 1995 to July 2010 using search terms that included spasticity, stroke, hemiplegia, phenol, baclofen, tizanidine, dantrolene, benzodiazepine, and botulinum toxin. The level of evidence of the identified publications was assessed using the Oxford Centre for Evidence-Based Medicine criteria. Results: A total of 113 potentially relevant articles were identified by the search; of these, 54 studies were included in the review (23 randomized controlled trials [RCTs] and 31 open-label, nonrandomized, or observational studies). Of these, 51 involved treatment with botulinum toxin (BTX). All studies assessed spasticity; some also assessed additional outcomes, such as pain, disability, and functional status. Thirty-eight clinical trials reported a significant reduction in spasticity with BTX, either compared with baseline or with placebo (P < 0.05). A head-to-head comparison found a significant reduction in spasticity with BTX injections compared with oral tizanidine (TZD) (P < 0.001). Two studies of intrathecal baclofen (ITB) reported significant reductions in upper limb spasticity after 12 months of treatment, and 1 study of tizanidine reported significant reductions in upper limb spasticity after 16 weeks of treatment (all, P < 0.001). General or local weakness, injection-site pain, and fatigue were the most frequently reported adverse events with BTX type A, and dry mouth was the most frequently reported adverse event with BTX type B. No serious or life-threatening adverse events were reported in any trial of BTX. Conclusions: The 54 studies included in this systematic review of treatments for upper limb spasticity after stroke measured multiple outcomes using a variety of instruments. Fifty-one studies focused on treatment with a BTX formulation. BTX appeared to be an effective and well-tolerated focal treatment for reducing tonicity in patients with upper limb spasticity after stroke, supporting current guideline recommendations.",
keywords = "Botulinum toxin, Spasticity, Stroke",
author = "Olvey, {Eleanor L.} and Armstrong, {Edward P} and Jones-Grizzle, {Amy J}",
year = "2010",
month = "12",
doi = "10.1016/j.clinthera.2011.01.005",
language = "English (US)",
volume = "32",
pages = "2282--2303",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "14",

}

TY - JOUR

T1 - Contemporary Pharmacologic Treatments for Spasticity of the Upper Limb After Stroke

T2 - A Systematic Review

AU - Olvey, Eleanor L.

AU - Armstrong, Edward P

AU - Jones-Grizzle, Amy J

PY - 2010/12

Y1 - 2010/12

N2 - Background: Muscle spasticity after stroke may be painful and severe and may restrict the patient's ability to perform routine daily tasks, particularly when the affected muscles are in the upper limbs. Treatments targeted at reducing this spasticity have evolved over time. Objective: This was a systematic review of recent studies focusing on contemporary pharmacologic therapies for upper limb spasticity after stroke. Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched for clinical trials published in English from January 1995 to July 2010 using search terms that included spasticity, stroke, hemiplegia, phenol, baclofen, tizanidine, dantrolene, benzodiazepine, and botulinum toxin. The level of evidence of the identified publications was assessed using the Oxford Centre for Evidence-Based Medicine criteria. Results: A total of 113 potentially relevant articles were identified by the search; of these, 54 studies were included in the review (23 randomized controlled trials [RCTs] and 31 open-label, nonrandomized, or observational studies). Of these, 51 involved treatment with botulinum toxin (BTX). All studies assessed spasticity; some also assessed additional outcomes, such as pain, disability, and functional status. Thirty-eight clinical trials reported a significant reduction in spasticity with BTX, either compared with baseline or with placebo (P < 0.05). A head-to-head comparison found a significant reduction in spasticity with BTX injections compared with oral tizanidine (TZD) (P < 0.001). Two studies of intrathecal baclofen (ITB) reported significant reductions in upper limb spasticity after 12 months of treatment, and 1 study of tizanidine reported significant reductions in upper limb spasticity after 16 weeks of treatment (all, P < 0.001). General or local weakness, injection-site pain, and fatigue were the most frequently reported adverse events with BTX type A, and dry mouth was the most frequently reported adverse event with BTX type B. No serious or life-threatening adverse events were reported in any trial of BTX. Conclusions: The 54 studies included in this systematic review of treatments for upper limb spasticity after stroke measured multiple outcomes using a variety of instruments. Fifty-one studies focused on treatment with a BTX formulation. BTX appeared to be an effective and well-tolerated focal treatment for reducing tonicity in patients with upper limb spasticity after stroke, supporting current guideline recommendations.

AB - Background: Muscle spasticity after stroke may be painful and severe and may restrict the patient's ability to perform routine daily tasks, particularly when the affected muscles are in the upper limbs. Treatments targeted at reducing this spasticity have evolved over time. Objective: This was a systematic review of recent studies focusing on contemporary pharmacologic therapies for upper limb spasticity after stroke. Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched for clinical trials published in English from January 1995 to July 2010 using search terms that included spasticity, stroke, hemiplegia, phenol, baclofen, tizanidine, dantrolene, benzodiazepine, and botulinum toxin. The level of evidence of the identified publications was assessed using the Oxford Centre for Evidence-Based Medicine criteria. Results: A total of 113 potentially relevant articles were identified by the search; of these, 54 studies were included in the review (23 randomized controlled trials [RCTs] and 31 open-label, nonrandomized, or observational studies). Of these, 51 involved treatment with botulinum toxin (BTX). All studies assessed spasticity; some also assessed additional outcomes, such as pain, disability, and functional status. Thirty-eight clinical trials reported a significant reduction in spasticity with BTX, either compared with baseline or with placebo (P < 0.05). A head-to-head comparison found a significant reduction in spasticity with BTX injections compared with oral tizanidine (TZD) (P < 0.001). Two studies of intrathecal baclofen (ITB) reported significant reductions in upper limb spasticity after 12 months of treatment, and 1 study of tizanidine reported significant reductions in upper limb spasticity after 16 weeks of treatment (all, P < 0.001). General or local weakness, injection-site pain, and fatigue were the most frequently reported adverse events with BTX type A, and dry mouth was the most frequently reported adverse event with BTX type B. No serious or life-threatening adverse events were reported in any trial of BTX. Conclusions: The 54 studies included in this systematic review of treatments for upper limb spasticity after stroke measured multiple outcomes using a variety of instruments. Fifty-one studies focused on treatment with a BTX formulation. BTX appeared to be an effective and well-tolerated focal treatment for reducing tonicity in patients with upper limb spasticity after stroke, supporting current guideline recommendations.

KW - Botulinum toxin

KW - Spasticity

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=79951816984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951816984&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2011.01.005

DO - 10.1016/j.clinthera.2011.01.005

M3 - Article

C2 - 21353101

AN - SCOPUS:79951816984

VL - 32

SP - 2282

EP - 2303

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 14

ER -